In summary, while the clinical benefits of SGLT2 inhibitors in HF are well established, a deeper understanding of their multifaceted mechanisms could not only clarify their therapeutic impact but also provide broader insights into HF pathophysiology and new treatment opportunities. Here, SLC5A2 is linked to hydrops fetalis.